Novocure Ltd
NASDAQ:NVCR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
10.9
30.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
NVCR
stock under the Base Case scenario is
20
USD.
Compared to the current market price of 13.48 USD,
Novocure Ltd
is
Undervalued by 33%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Novocure Ltd.
| US |
|
Abbott Laboratories
NYSE:ABT
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Revenue & Expenses Breakdown
Novocure Ltd
Balance Sheet Decomposition
Novocure Ltd
| Current Assets | 1.2B |
| Cash & Short-Term Investments | 1B |
| Receivables | 124.7m |
| Other Current Assets | 41.6m |
| Non-Current Assets | 161.3m |
| PP&E | 148.9m |
| Other Non-Current Assets | 12.4m |
| Current Liabilities | 776m |
| Accounts Payable | 118.9m |
| Short-Term Debt | 560.6m |
| Other Current Liabilities | 96.5m |
| Non-Current Liabilities | 243.9m |
| Long-Term Debt | 194.6m |
| Other Non-Current Liabilities | 49.2m |
Free Cash Flow Analysis
Novocure Ltd
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Novocure Ltd
|
Revenue
|
642.3m
USD
|
|
Cost of Revenue
|
-156.9m
USD
|
|
Gross Profit
|
485.4m
USD
|
|
Operating Expenses
|
-661m
USD
|
|
Operating Income
|
-175.6m
USD
|
|
Other Expenses
|
-2m
USD
|
|
Net Income
|
-177.7m
USD
|
NVCR Profitability Score
Profitability Due Diligence
Novocure Ltd's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
Novocure Ltd's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
NVCR Solvency Score
Solvency Due Diligence
Novocure Ltd's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Score
Novocure Ltd's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NVCR Price Targets Summary
Novocure Ltd
According to Wall Street analysts, the average 1-year price target for
NVCR
is 25.28 USD
with a low forecast of 13.64 USD and a high forecast of 44.1 USD.
Dividends
Current shareholder yield for
NVCR is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
NVCR
stock under the Base Case scenario is
20
USD.
Compared to the current market price of 13.48 USD,
Novocure Ltd
is
Undervalued by 33%.